GlassScriptPhysician profile
Muhammad Afzal
NPI 1417096629
$5,065.36
in general payments reported to CMS, 2019-2025
30 companies · $270 in 2025
The $270 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.17 · 2020: $732 · 2021: $2,288 · 2022: $747 · 2023: $475 · 2024: $516 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226 · Education: $34.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.30 |
| Education | $34.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $1,325.97 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $916.10 | 2020-2025 | Farxiga |
| Amgen INC. | $538.09 | 2020-2025 | Tavneos, Krystexxa |
| Novartis Pharmaceuticals Corporation | $319.04 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $250.12 | 2021-2024 | |
| Daiichi Sankyo INC. | $196.29 | 2020-2023 | Injectafer |
| Vifor Pharma, INC. | $195.26 | 2020-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $166.42 | 2020-2024 | Jynarque |
| Opko Pharmaceuticals, LLC | $135.70 | 2020-2023 | Rayaldee |
| Aurinia Pharma U.S., INC. | $135.05 | 2021-2024 | Lupkynis |
| Akebia Therapeutics INC | $100.05 | 2020-2022 | |
| Novo Nordisk INC | $86.50 | 2022-2025 | Ozempic, Rybelsus |
| Becton, Dickinson and Company | $73.16 | 2024 | |
| Baxter Healthcare | $67.50 | 2019-2020 | |
| Calliditas Therapeutics US INC. | $66.16 | 2022-2025 | Tarpeyo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $63.78 | 2020-2022 | |
| Veloxis Pharmaceuticals, INC. | $59.15 | 2020 | |
| Horizon Therapeutics Plc | $56.39 | 2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $46.12 | 2021-2024 | Ultomiris |
| Glaxosmithkline, LLC. | $42.70 | 2021-2023 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.20 | 2023-2025 | Jardiance |
| Nuwellis, INC. | $30.96 | 2020 | |
| Vantive US Healthcare LLC | $23.10 | 2025 | Renal - Pd |
| Mallinckrodt Hospital Products INC. | $22.62 | 2020 | |
| Abbott Laboratories | $21.97 | 2025 | Cardiomems |
| Travere Therapeutics, INC. | $21.57 | 2022-2025 | Filspari |
| Ardelyx, INC. | $20.51 | 2024 | Ibsrela |
| Apellis Pharmaceuticals, INC. | $18.43 | 2025 | |
| Pharmacosmos Therapeutics INC. | $17.09 | 2023 | Monoferric |
| Ultragenyx Pharmaceutical INC. | $16.36 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Afzal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.